Market News & Trends
Protea Announces Completion of Human Clinical Trial for New Biopharmaceutical
Protea Biosciences, a leading developer of new technology for pharmaceutical research, recently announced that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has…
Rhenovia Enters Strategic Alliance With Portmann Instruments
Rhenovia Pharma SAS, a biotechnology company specialized in the development and optimization of treatments for diseases of the central and peripheral nervous systems, recently announced…
6/7/2011
Avantor Performance Materials Expands Presence in India Avantor Performance Materials recently announced it has opened a new pharmaceuticals formulation applications laboratory at the RanQ Remedies…
PolyPid Announces Revolutionary Drug Delivery System
PolyPid, a developer of innovative drug carriers, recently announced the company's flagship platform - PolyPid, an innovative family of drug carriers, based on a fusion…
Sartorius Stedim Biotech & RAUMEDIC Sign Partnership Agreement
Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and RAUMEDIC, a leading worldwide OEM manufacturer of medical- and pharmaceutical-grade polymer components and…
Talon Therapeutics to Commence Phase III Study of Marqibo
Talon Therapeutics, Inc. recently announced the initiation of a Phase III study of Marqibo (vincristine sulfate liposomes injection) in elderly patients with newly diagnosed aggressive…
TxCell Receives Approval for Phase I/II Clinical Trial Extension
TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, recently announced the approval…
Critical Outcome Technologies Initiates Development of Optimal Oral Oncology Formulation
Critical Outcome Technologies Inc. recently announced it has initiated a project to develop an optimal oral formulation of COTI-2. This lead oncology product has demonstrated…
Infinity Initiates Randomized Phase II Trial of Novel Hsp90 Inhibitor
Infinity Pharmaceuticals, Inc. recently announced the initiation of a Phase II clinical trial of retaspimycin hydrochloride (HCl), also known as IPI-504, the company's novel heat…
5/24/2011
Sartorius Stedim Biotech & RAUMEDIC Sign Partnership Agreement Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and RAUMEDIC, a leading worldwide OEM…
5/10/2011
QRxPharma Completes Patient Enrolment of Phase III Comparative Safety Study QRxPharma Limited recently announced it has completed patient enrolment for Study 022, a Phase III…
Avantor Performance Materials to Acquire POCH S.A.
Avantor Performance Materials announced a definitive agreement to acquire POCH S.A. from Kulczyk. Completion of the sale is dependent upon obtaining the necessary clearance from…
Axcan & Eurand Announce Name Change
Axcan Intermediate Holdings Inc. recently announced it is changing its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies…
MicroDose Therapeutx Announces Development Milestone Triggering Payment Under Respiratory Collaboration
MicroDose Therapeutx, Inc. recently announced that a development milestone in its collaboration with Novartis has been achieved, triggering a payment under the multi-product development and…
Nabi Biopharmaceuticals Completes Final Milestone; $5 Million Payment Received
Nabi Biopharmaceuticals recently announced it has completed the Phase I trial for two of the PentaStaph antigens that began in December 2009. Completion of this…
Novozymes Biopharma Collaborates With University to Tailor the Half-Lives of Proteins
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, recently unveiled its enhanced next-generation albumin technology, which was developed in collaboration with the…
QRxPharma Completes Patient Enrolment of Phase III Comparative Safety Study
QRxPharma Limited recently announced it has completed patient enrolment for Study 022, a Phase III trial comparing the tolerability and safety profile of MoxDuo IR…
Gilead & MicroDose Therapeutx Announce License & Collaboration Agreement
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. recently announced they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization…
Precision NanoSystems & Alnylam Form New Delivery Collaboration
Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, recently announced the two companies have formed an exclusive collaboration focused on the…
Avantor Certifies All Doe & Ingalls Sites Under Certified Excipient Distributor Program
Avantor Performance Materials (formerly Mallinckrodt Baker) recently announced that Doe & Ingalls, a national chemical services provider and Avantor distributor, is the first distributor to…
